Antibiotic Resistance Market Size is valued at 8.93 Billion in 2024 and is predicted to reach 16.99 Billion by the year 2034 at a 6.8% CAGR during the forecast period for 2025-2034.
Antibiotics are antimicrobial chemicals that are used to treat bacterial infections. Strokes, sinus infections, urinary tract infections, ear infections, pneumonia, skin infections, and other diseases are all treated with them. The market has been supported by the high prevalence of antibiotic-resistance illnesses, and the rise of multi-drug resistant bacteria are expected to boost the market expansion in the next coming years. In addition, the accelerated need for novel therapies will further provide potential opportunities for the growth of the antibiotic resistance market over the upcoming years. The discovery of advanced prospect molecules and the introduction of novel combination therapies to treat antibiotic-resistant microbial infections are expected to propel the market growth during the forecast period.
However, lack of investor concern in the research and development of resistance therapies, shortage of educated employees and strict safety rules are factors that may limit the growth of the target market during the forecast period. Advances in nutrition, medicine, and vaccination are factors that are likely to generate profitable revenue growth possibilities for participants in the worldwide Antibiotic Resistance market throughout the forecast period.
The antibiotic resistance market is segmented on the basis of disease, pathogen, drug class, mechanism of action, and distribution channel. Based on disease, the market is segmented into cUTI (complicated urinary tract infections), CDI (Clostridioides difficile infection), ABSSSI (acute bacterial skin and skin structure infections), HABP (hospital-acquired bacterial pneumonia), CABP (community-acquired pneumonia), cIAI (complicated intra-abdominal infection), and BSI (bloodstream infection). Based on pathogen, the market is segmented into E. coli, K. pneumoniae, P. aeruginosa, S. aureus, A. baumannii, S. pneumoniae, H. influenzae, C. difficile, and E. faecium. Based on drug class, the market is segmented into oxazolidinones, lipoglycopeptides, tetracyclines, combination therapies, cephalosporins, and others. Based on mechanism of action, the market is segmented into protein synthesis inhibitors, cell wall synthesis inhibitors, RNA synthesis inhibitors, DNA synthesis inhibitors, and others. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
Based on disease, the cUTI segment dominates the antibiotic resistance market due to the rising incidence of complicated urinary tract infections, which are frequently caused by multidrug-resistant pathogens such as E. coli and K. pneumoniae. These infections often require advanced broad-spectrum or novel antibiotics, creating significant demand for effective therapies. Increasing hospitalizations, aging populations, and recurrent UTI cases further drive the segment's growth
The North America Antibiotic Resistance market is expected to register the highest market share in terms of revenue soon. The regional market's expansion is being aided by several new medicine launches and significant treatment costs. North America and Europe are growing their use of the antibiotic resistance sector as a result of greater individual awareness regarding antibiotic resistance in this region. Antibiotic-resistant infections are on the rise, and healthcare-acquired conditions are on the increase in the United States.
In addition, Europe is projected to grow at a rapid rate in the global Antibiotic Resistance market. Greater engagement in terms of investment to combat resistance and implementing proper usage and stewardship standards for the use of antibiotics will boost market expansion over the upcoming years. The increased acceptance of antibiotic resistance and the increasing incidence of infectious diseases are some of the prior causes projected to drive the evolution of the antibiotic resistance marker.
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 8.93 Billion |
|
Revenue Forecast In 2031 |
USD 16.99 Billion |
|
Growth Rate CAGR |
CAGR of 6.8% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Disease, Pathogen, Drug Class, Mechanism Of Action, And Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; South East Asia |
|
Competitive Landscape |
The Medicines Company, Melinta Therapeutics, Arsanis, Phage Technologies S.A, Westway Health, Alaxia SAS, Antabio S.A.S, Auspherix Ltd, BioFilm Pharma, Centauri Therapeutics Ltd, Combioxin SA, Da Volterra, Debiopharm International SA, Deinove, Neem Biotech Ltd, Northern,, Antibiotics Oy (Ltd), Nosopharm, NovaBiotics Ltd, Phico Therapeutics Ltd, Polyphor Ltd, QureTech Bio AB,SetLance Srl, Ultupharma AB, Vaxdyn, Vibiosphen, Bioaster, Vivexia, KBP Biosciences, Absynth Biologics, Spero Therapeutics, Merck, Symphogen, Warp Drive Bio, Johnson & Johnson (Janssen), Pfizer, Allergan, Novartis, AstraZeneca, Cipla, DSM Sinochem Pharmaceuticals, Wockhardt Ltd., VenatoRx Pharmaceuticals, MicuRx, Entasis Therapeutics, Merlion Pharmaceuticals, Aridis Pharmaceuticals Inc, and others |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Antibiotic Resistance Market Snapshot
Chapter 4. Global Antibiotic Resistance Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.9. Use/impact of AI on Antibiotic Resistance Market Industry Trends
4.10. Global Antibiotic Resistance Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. Antibiotic Resistance Market Segmentation 1: By Pathogen, Estimates & Trend Analysis
5.1. Market Share by Pathogen, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Pathogen:
5.2.1. E. coli
5.2.2. K. pneumoniae
5.2.3. P. aeruginosa
5.2.4. S. aureus
5.2.5. A. baumannii
5.2.6. S. pneumoniae
5.2.7. H. influenzae
5.2.8. C. difficile
5.2.9. E. faecium
Chapter 6. Antibiotic Resistance Market Segmentation 2: By Disease, Estimates & Trend Analysis
6.1. Market Share by Disease, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Disease:
6.2.1. cUTI (Complicated Urinary Tract Infections)
6.2.2. CDI (Clostridioides difficile Infection)
6.2.3. ABSSSI (Acute bacterial skin and skin structure infections)
6.2.4. HABP (Hospital-acquired bacterial pneumonia)
6.2.5. CABP (Community-acquired pneumonia)
6.2.6. cIAI (Complicated intra-abdominal infection)
6.2.7. BSI (Bloodstream infection)
Chapter 7. Antibiotic Resistance Market Segmentation 3: By Drug Class, Estimates & Trend Analysis
7.1. Market Share by Drug Class, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Drug Class:
7.2.1. Oxazolidinones
7.2.2. Lipoglycopeptides
7.2.3. Tetracyclines
7.2.4. Combination therapies
7.2.5. Cephalosporins
7.2.6. Others
Chapter 8. Offline Antibiotic Resistance Market Segmentation 4: By Mechanism of Action, Estimates & Trend Analysis
8.1. Market Share by Mechanism of Action, 2024 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Mechanism of Action:
8.2.1. Protein Synthesis Inhibitors
8.2.2. Cell Wall Synthesis Inhibitors
8.2.3. RNA Synthesis Inhibitors
8.2.4. DNA Synthesis Inhibitors
8.2.5. Others
Chapter 9. Antibiotic Resistance Market Segmentation 5: By Distribution Channel, Estimates & Trend Analysis
9.1. Market Share by Distribution Channel, 2024 & 2034
9.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Distribution Channel:
9.2.1. Hospital Pharmacies
9.2.2. Retail Pharmacies
9.2.3. Online Pharmacies
Chapter 10. Antibiotic Resistance Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global Antibiotic Resistance Market, Regional Snapshot 2024 & 2034
10.2. North America
10.2.1. North America Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Pathogen, 2021-2034
10.2.3. North America Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2021-2034
10.2.4. North America Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2021-2034
10.2.5. North America Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Mechanism of Action, 2021-2034
10.2.6. North America Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
10.3. Europe
10.3.1. Europe Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Pathogen, 2021-2034
10.3.3. Europe Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2021-2034
10.3.4. Europe Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2021-2034
10.3.5. Europe Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Mechanism of Action, 2021-2034
10.3.6. Europe Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
10.4. Asia Pacific
10.4.1. Asia Pacific Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Pathogen, 2021-2034
10.4.3. Asia Pacific Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2021-2034
10.4.4. Asia Pacific Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts Mechanism of Action, 2021-2034
10.4.5. Asia Pacific Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
10.5. Latin America
10.5.1. Latin America Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Pathogen, 2021-2034
10.5.3. Latin America Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2021-2034
10.5.4. Latin America Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2021-2034
10.5.5. Latin America Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Mechanism of Action, 2021-2034
10.5.6. Latin America Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
10.6. Middle East & Africa
10.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Pathogen, 2021-2034
10.6.3. Middle East & Africa Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2021-2034
10.6.4. Middle East & Africa Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2021-2034
10.6.5. Middle East & Africa Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Mechanism of Action, 2021-2034
10.6.6. Middle East & Africa Antibiotic Resistance Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. The Medicines Company
11.2.1.1. Business Overview
11.2.1.2. Key Pathogen/Service Overview
11.2.1.3. Financial Performance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy
11.2.2. Melinta Therapeutics
11.2.3. Arsanis
11.2.4. Phage Technologies S.A
11.2.5. Westway Health
11.2.6. Tetraphase Pharmaceuticals
11.2.7. BioVersys GmbH
11.2.8. Nabriva Therapeutics.
11.2.9. Macrolide Pharmaceuticals
11.2.10. Nemesis Bioscience
11.2.11. C3J Therapeutics, Inc
11.2.12. EpiBiome
11.2.13. discuva
11.2.14. SmartPhage
11.2.15. AmpliPhi Biosciences
11.2.16. Pherecydes Pharma
11.2.17. Micreos
11.2.18. Procarta Biosystems
11.2.19. Lumavita
11.2.20. Madam Therapeutics
11.2.21. Priaxon
11.2.22. Biolytx Pharmaceuticals
11.2.23. AntibioTx
11.2.24. Xellia Pharmaceuticals
11.2.25. Paratek Pharmaceuticals
11.2.26. Synereca Pharmaceuticals
11.2.27. Allecra Therapeutics
11.2.28. Fixed Phage
11.2.29. Enanta Pharmaceuticals, Inc
11.2.30. Demuris
11.2.31. Prommune
11.2.32. Biosergen
11.2.33. Innovation Pharmaceuticals
11.2.34. Aviragen Therapeutics
11.2.35. Achillion Pharmaceuticals
11.2.36. ImmunNovative Developments, S.L.
11.2.37. Achaogen, Inc.
11.2.38. SelectX Pharmaceuticals, Inc.
11.2.39. TaiGen Biotechnology Co., Ltd
11.2.40. Theravance Biopharma
11.2.41. Abbvie
11.2.42. KYORIN Pharmaceutical Co., Ltd.
11.2.43. Iterum Therapeutics Limited
11.2.44. Forge Therapeutics
11.2.45. Alopexx Vaccine LLC
11.2.46. Integrated Biotherapeutics
11.2.47. Hennepin Life Sciences
11.2.48. Fedora Pharmaceuticals Inc
11.2.49. Contrafect Corporation
11.2.50. Basilea Pharmaceutica Ltd.
11.2.51. AiCuris
11.2.52. RedHill Biopharma
11.2.53. Redx Pharma Plc/ Redx Anti Infectives Ltd.
11.2.54. ABAC Therapeutics
11.2.55. Alaxia SAS
11.2.56. Antabio S.A.S
11.2.57. Auspherix Ltd
11.2.58. BioFilm Pharma
11.2.59. Centauri Therapeutics Ltd
11.2.60. Combioxin SA
11.2.61. Da Volterra
11.2.62. Debiopharm International SA
11.2.63. Deinobiotics/Deinove
11.2.64. Destiny Pharma plc
11.2.65. Eligo Bioscience
11.2.66. Helperby Therapeutics Ltd
11.2.67. Karveel Pharmaceuticals
11.2.68. MaaT Pharma
11.2.69. Motif BioSciences, Inc / Motif Bio PLC
11.2.70. Mutabilis SAS
11.2.71. Neem Biotech Ltd
11.2.72. Northern Antibiotics Oy (Ltd)
11.2.73. Nosopharm
11.2.74. NovaBiotics Ltd
11.2.75. Phico Therapeutics Ltd
11.2.76. Polyphor Ltd
11.2.77. QureTech Bio AB
11.2.78. SetLance Srl
11.2.79. Ultupharma AB
11.2.80. Vaxdyn
11.2.81. Vibiosphen
11.2.82. Bioaster
11.2.83. Vivexia
11.2.84. KBP Biosciences
11.2.85. Absynth Biologics
11.2.86. Spero Therapeutics
11.2.87. Merck
11.2.88. Symphogen
11.2.89. Warp Drive Bio
11.2.90. Johnson & Johnson (Janssen)
11.2.91. Pfizer
11.2.92. Allergan
11.2.93. Novartis
11.2.94. AstraZeneca
11.2.95. Cipla
11.2.96. DSM Sinochem Pharmaceuticals
11.2.97. Wockhardt Ltd.
11.2.98. VenatoRx Pharmaceuticals
11.2.99. MicuRx
11.2.100. Entasis Therapeutics
11.2.101. Merlion Pharmaceuticals
11.2.102. Aridis Pharmaceuticals Inc.
11.2.103. Other Prominent Players
By Pathogen
By Disease
By Drug Class
By Mechanism of Action
By Distribution Channel
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Rest of Middle East and Africa
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
